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Abstract
Background: A relationship between hospitalization for respiratory syncytial virus (RSV) bronchiolitis and asthma
development has been suggested in case-control studies.
Objective: The aim of this study was to assess the risk of current wheeze, asthma, and lung function at school age in infants
previously hospitalized for RSV bronchiolitis compared to non-hospitalized children.
Methods: For this study, data from a prospective birth cohort of unselected, term-born infants (n = 553), of whom 4 (0.7%)
were hospitalized for RSV bronchiolitis, and a prospective patient cohort of 155 term infants hospitalized for RSV
bronchiolitis were used. Respiratory outcomes at age 6 in children hospitalized for RSV bronchiolitis were compared to non-
hospitalized children.
Results: The risk of current wheeze was higher in hospitalized patients (n = 159) compared to non-hospitalized children
(n = 549) (adjusted odds ratio (OR) 3.2 (95% CI 1.2–8.1). Similarly, the risk of current asthma, defined as a doctor’s diagnosis
of asthma plus current symptoms or medication use, was higher in hospitalized patients (adjusted OR 3.1 (95% CI 1.3–7.5).
Compared to non-hospitalized children, RSV bronchiolitis hospitalization was associated with lower lung function (mean
difference FEV1% predicted 26.8 l (95% CI (210.2 to 23.4).
Conclusions and Clinical Relevance: This is the first study showing that hospitalization for RSV bronchiolitis during infancy
is associated with increased risk of wheezing, current asthma, and impaired lung function as compared to an unselected
birth cohort at age 6.
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Introduction
Respiratory syncytial virus (RSV) infection is a common cause
of severe bronchiolitis in infants. The annual global incidence of
RSV infection in children younger that 5 years, has been
estimated at 34 million per year, with at least 10% episodes
representing severe infections that require hospitalization [1].
Over the last 20 years, epidemiologic studies have shown an
association between RSV bronchiolitis and the subsequent
development of wheeze and asthma up to school age [2]. Most
studies had a case-control design [3–7], which bears the challenge
of control selection. In order to prevent selection bias, sampling of
controls needs to be independent of the determinant studied [8].
The ALSPAC study retrospectively analyzed the relationship
between a discharge code of hospitalization for RSV bronchiolitis
and long-term airway disease up to age 7 years within in the study
registry [9]. In that study there was an excess of subjects with
missing data among RSV cases. A recent meta-analysis concluded
that study quality of follow-up studies after RSV bronchiolitis was
generally poor [10]. For that reason Stein and Martinez argued
that the association between RSV hospitalization during infancy
and asthma at school has still not been established [11]. To our
knowledge, no study has prospectively compared wheezing and
lung function at school age between term hospitalized RSV
bronchiolitis patients and a large birth cohort of healthy term
children. We performed a prospective cohort study of healthy
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e87162
infants, including a group of well characterized, hospitalized RSV
infants with bronchiolitis [12]. Our aim was to determine whether
the risk of wheeze and asthma at age 6 is related to RSV
bronchiolitis hospitalization during infancy.
Materials and Methods
Participants
The WHISTLER project is an ongoing population based,
prospective birth cohort on determinants of wheezing illnesses in
children, which started in December 2001. Participants are
healthy, term-born infants born in Leidsche Rijn, a residential
area near the city of Utrecht. Infants are enrolled at the age of 2
weeks, and are prospectively followed with (1) a diary for
respiratory symptoms in the first year of life, and with (2) study
visits including lung function at age 5 and 8 [12]. For each
participant, data from the most recent study visit was used (either
from the visit at age 5 or age 8), resulting in 553 children of similar
age for analysis. Children that were hospitalized during infancy for
a proven RSV bronchiolitis (positive immunofluorescence test or
PCR) were identified. This birth cohort was compared to a cohort
of children that had been hospitalized for RSV bronchiolitis.
Summarized, between 2004 and 2006, 243 previously healthy
infants aged less than 13 months were admitted to the hospital
with an RSV infection, as described earlier in detail [13]. Patients
with a proven RSV bronchiolitis by a positive immunofluores-
cence test for RSV in epithelial cells from nasopharyngeal
aspirates were randomly assigned to receive either high dose
extra fine HFA beclomethasone dipropionate or placebo. At age 6,
no differences in lung function or presence of respiratory
symptoms were found between groups, and therefore we
combined both groups for the current report. All children were
invited to participate in the follow-up study visit at 6 years of age,
including a questionnaire, and lung function assessment. From
April 2010 to November 2011, 185 (76%) children attended this
study visit (Figure S1). Only term born infants (155/185) were
included, and added to the 4 hospitalized RSV bronchiolitis
patients in the Whistler cohort. Respiratory outcomes of hospital-
ized RSV bronchiolitis patients within the complete cohort
(n = 159, hereafter called hospitalized patients), were compared
to non-hospitalized children (n= 549). Parents gave written
informed consent for study participation.
Ethics Statement
The medical ethics committee of the University Medical Centre
Utrecht approved both studies. Written informed parent consent
was obtained from all parents. The study was conducted according
to the principles of the Declaration of Helsinki (version 2000) and
in accordance with the Dutch Medical Research Involving
Human Subjects Act (WMO). Good Clinical Practice (GCP)
guidelines were followed.
Outcomes
Questionnaire and definitions. The questionnaire con-
tained standardized questions about atopic diseases from the
ISAAC questionnaire [14], medication use (e.g. antihistamines,
inhalation steroids and beta-mimetics) in the last 12 months and
known risk factors for atopic diseases (i.e. positive family history).
All questions were filled in by the parents of the hospitalized
patients and non-hospitalized children. Parental allergy was
defined as a questionnaire-reported allergy to pollen, house dust
mite, pets or food. Smoke exposure was defined as smoking of one
of the parents in the last 5 years of life, and data from the first year
of life were used to obtain information about smoke exposure in
the first year of life to prevent recall bias. A non-western origin was
defined as a country of birth in Asia (including Turkey), Africa,
Latin America, excluding Indonesia and Japan. In the Nether-
lands, children regularly visit child healthcare centers for
standardized anthropometry. These measurements are recorded
in a personal file for every child, kept by parents. Parents were
asked to use this file to report these anthropometric measures in
the questionnaire. Current wheeze, in both the hospitalized
patients and non-hospitalized children, was defined as a positive
response to the question ‘‘Has your child had wheezing or
whistling in the chest in the last 12 months?’’ Current asthma was
defined as a history of doctor’s diagnosis of asthma plus asthma
symptoms or medication (beta-mimetics or inhaled corticosteroids)
use in the last 12 months.
A doctor’s diagnosis of asthma ever was defined as an ever
recorded asthma diagnosis from the general practitioner after a
primary care visit (R03 wheezing, R96 asthma), according to the
International Classification of Primary Care (ICPC) [15].
Lung function. Spirometry was performed using a calibrated
spirometer (Zan 100 pulmonary spirometer system (nSpire, USA).
Maximal flow-volume curves were measured according to the
ATS/ERS standards [20]. The largest forced expiratory volume in
1 second (FEV1), forced vital capacity (FVC) and peak expiratory
flow (PEF) were selected from three correctly performed manoeu-
vres. Results were related to Dutch normative values [16].
Expiratory measurements of respiratory system resistance (Rint)
were obtained using MicroRint (Micro Medical Limited, Kent,
UK). Mean Rint was calculated from at least 5 acceptable
interruptions. FeNO was measured in exhaled breath using the
NioxMino (NIOX; Aerocrine AB, Solna, Sweden). All children
withheld their rescue medication for at least 12 hours beforehand.
If the child had suffered from a respiratory tract infection in the
last 2 weeks, the test was postponed.
Statistical analysis. Logistic regression was used to investi-
gate the effect of RSV bronchiolitis hospitalization on current
wheeze and asthma. Hereafter, multivariable analysis was used to
adjust for possible confounders influencing both current wheeze or
asthma (outcomes) as well as RSV bronchiolitis hospitalization
(determinant). Results are presented as odds ratio (OR) with a
95% confidence interval (CI). Linear regression was used to
investigate the effect of RSV bronchiolitis hospitalization on lung
function. Again, multivariable analyses was used to adjust for
possible confounders, and results are presented as crude and
adjusted mean differences with a 95% CI. Data were analyzed
using PASW Statistics 18 (version 18.0.0, SPSS Inc., 2009,
Chicago USA).
Confounders. Baseline characteristics between the two
cohorts were likely to be different with respect to risk factors for
RSV bronchiolitis hospitalization. These risk factors were consid-
ered to be potential confounders of the association between RSV
hospitalization and current wheeze or asthma. The following
confounders were corrected for in our analysis: male gender,
breastfeeding, siblings, day care attendance, smoke exposure, birth
weight, being born between April and September, year of birth,
and educational level of the mother.
Results
Of the 243 hospitalized RSV bronchiolitis patients that
participated in the initial trial, 185 participated in the follow-up
study. 155 Previously healthy, term infants were selected for
further analyses, of whom 113 (72.9%) agreed to take part in the
lung function test (figure S1). Non-participants were more often of
non-Caucasian ethnicity compared to participants or the excluded
RSV, Wheeze and Lung Function
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premature born participants (table S1). Participants with a
successful lung function measurement were significantly younger
compared to participants with unsuccessful lung function mea-
surement (5.8 versus 6.3 years, p,0.001, table S2). Children
hospitalized for RSV bronchiolitis had lower birth weight, were
more often born between September and March, more often
exposed to maternal smoking in pregnancy, less often breastfed,
did go to daycare less often, had more often siblings, had lower
educated parents and more often Caucasian parents compared to
non-hospitalized children (table 1).
Current Wheeze, Asthma and Allergic Diseases
In the univariable logistic regression analysis hospitalized RSV
bronchiolitis patients had a 3.2 fold increased odds for wheeze in
the last 12 months (table 2). Hospitalized RSV patients more often
were diagnosed with asthma at any point in life, and a higher
proportion had current asthma defined as a history of doctor’s
diagnosis of asthma plus asthma symptoms or medication use in
the last 12 months. Hospitalized patients more often used airway
medication compared to non-hospitalized children, however this
did not reach statistical significance. In multivariable analysis we
initially adjusted the risk of current wheeze and asthma for sex and
age only, but this did not change our results. We repeated our
analysis by adjusting for sex, age, birth weight, season of birth,
year of birth, smoke exposure during pregnancy and during life,
breastfeeding, daycare, siblings, maternal atopy and maternal
ethnicity. This slightly changed the odds for current wheeze and
current asthma to 3.2 (95% CI 1.2 to 8.1) and 3.1 (95%CI 1.3 to
7.5) respectively.
Comparable adjusted odds ratios were found for current wheeze
in atopic children (OR 3.7 (95% CI 0.8 to 15.6) and non-atopic
children (2.9 (95%CI 0.8 to 10.5), as well as for current asthma in
atopic (OR 3.3 (95% CI 0.8 to 13.6) and non-atopic children (2.6
(95%CI 0.8 to 8.8)). Proportions of parent-reported allergic
diseases in their children were not significantly different between
the hospitalized patients and non-hospitalized children (hay fever
5.7% versus 5.5%, and eczema 34.0% versus 27.5%).
Lung Function
Compared to the non-hospitalized children, lung function was
significantly impaired in the hospitalized RSV patients (table 3,
figure 1). Hospitalized patients had lower FEV1 (mean difference
(MD) 26.8 l. %predicted (95% CI 210.2 to 23.4), lower FVC
(MD 26.5 l. %predicted) (95% CI 210.4 to 22.7), a lower
Tiffeneau index (MD 22.0% (95% CI 23.6 to 20.3), higher
FeNO (MD 4.0 ppb (95% CI 1.9 to 6.2) and increased resistance
of the respiratory system (MD 15.6 kPa/L/s (95% CI 6.5 to 24.6)
compared to the non-hospitalized children.
Discussion
In this prospective study we studied the risk of wheeze and
asthma after RSV bronchiolitis hospitalization during infancy. We
established a 3.2 fold increased risk of current wheeze and a 3.1
fold increased risk of current asthma in hospitalized RSV
bronchiolitis patients compared to non-hospitalized children. In
hospitalized RSV bronchiolitis patients the mean FEV1 percent-
age predicted was 6.8% lower compared to non-hospitalized
children.
To our knowledge, this is the first study comparing prospectively
followed hospitalized infants with RSV bronchiolitis to a normal
birth cohort, and obtaining valid risk estimates on respiratory
morbidity in childhood. Late effects of RSV bronchiolitis requiring
hospitalization have previously been studied by others [3–5,9,17].
A study by Sigurs et al. [3] reported a 2 fold increased risk of ‘‘any
wheezing’’ in prospectively followed hospitalized RSV bronchiol-
Table 1. Group characteristics at age 6 for 159 hospitalized RSV bronchiolitis patients [13], and non-hospitalized children [12].
Hospitalized RSV
bronchiolitis patients
(n =159) Non-hospitalized (n =549) p-value
Sex (male) 87/159 (54.7) 265/549 (48.3) 0.153
Median age at follow-up in yrs (IQR) 5.88 (5.67–6.25) 5.33 (5.17–7.75) 0.923
Median age at hospitalisation (months) 2.0 (1.0–4.0) – –
Birth weight (g) 3250 (3250–3750) 3557 (3260–3860) ,0.001
Gestational age (weeks) 40.0 (39.0–40.6) 40.0 (39.1–40.9) 0.081
Born September-March 99/159 (62.3) 270/549 (49.2) 0.002
Smoking during pregnancy 27/155 (17.0) 26/548 (4.7) ,0.001
Smoke exposure up to age 6 42/159 (26.4) 126/451 (27.9) 0.721
Breastfed in first 3 months 97/155 (62.6) 3768/515 (71.5) 0.036
Daycare in first 3 months 52/155 (33.5) 227/515 (44.1) 0.020
Pets in first year of life 79/154 (51.3) 274/475 (57.7) 0.166
Siblings 134/155 (86.5) 297/548 (54.2) ,0.001
Maternal atopy 66/154 (42.9) 224/466 (48.1) 0.262
Maternal ethnicity Caucasian* 149/154 (96.8) 386/469 (82.3) ,0.001
Maternal high educational level 53/153 (34.6) 301/470 (64.0) ,0.001
Median height at age 6 (cm, IQR) 117.2 (113.0–126.10 118.2 (114.3–121.8) 0.094
Median weight at age 6 (kg, IQR) 21.0 (19.0–25.0) 21.6 (19.7–24.0) 0.567
Data are numbers (percentages) unless stated otherwise.
*Caucasian =Not born in Africa, Latin America and Asia (Japan and Indonesia excluded) or Turkey.
doi:10.1371/journal.pone.0087162.t001
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itis patients without concomitant chronic disease, whereas
Henderson et al. reported a 3.2–6.6 fold increased risk of wheeze
in hospitalized RSV patients selected from a large cohort study
[9]. Asthma prevalence in the control population was 3% in the
Sigurs study, which is much lower than in the general Swedish
population [18]. In our non-hospitalized group the prevalence of
wheeze and asthma was 8.1% and 5.3% respectively. These
numbers are comparable to the prevalence of wheeze and asthma
in 6–7 year old children in western surrounding countries [18],
indicating that this group reflects the general population of the
Netherlands with respect to wheeze and asthma.
Although symptoms may subside with age, lung function has
been shown to track over life [19]. Lung functions in the
hospitalized RSV patients were impaired compared to the non-
hospitalized children, and differences between groups were larger
than described in previous reports [4,20,21]. Lung function
decline could be of vital importance because low lung function
in adulthood is one of the strongest predictors of chronic airway
obstructive pulmonary disease later on in life [19].
The mechanism underlying long-term consequences of severe
RSV bronchiolitis is intriguing. Here, we confirm the results from
the Tucson study showing that atopy does not play a major role in
the development of wheeze and loss of lung function following
RSV infection. Numerous hypotheses explaining the association
between RSV bronchiolitis and asthma development have been
published, including innate immune mechanisms, adaptive
immune mechanisms as well as neurogenic mechanisms [22].
RSV bronchiolitis is associated with a strong local neutrophil






patients Non hospitalized Crude Adjusted* Adjusted**
(n =159) (n =549) OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Respiratory symptoms
Current wheeze 33/155 (21.3) 42/516 (8.1) 3.0 1.9–5.0 ,0.001 3.0 1.9–5.1 ,0.001 3.2 1.2–8.1 0.002
Current use of asthma
medication
Inhaled steroids 11/159 (6.9) 25/549 (6.9) 1.6 0.7–3.2 0.235 1.5 0.7–3.2 0.255 3.4 1.0–11.3 0.292




63/158 (39.9) 58/517 (11.2) 5.2 3.5–8.0 ,0.001 5.3 3.4–8.0 ,0.001 5.8 2.8–11.8 ,0.001
Current asthma*** 34/159 (21.4) 29/549 (5.3) 4.9 2.9–8.3 ,0.001 4.8 2.8–8.2 ,0.001 3.1 1.3–7.5 0.010
Data are numbers (percentages) unless stated otherwise;
*Adjusted for sex and age;
**Adjusted for sex, age, birth weight, birth season, smoke exposure during pregnancy and during life, breastfeeding, daycare, siblings, maternal atopy, ethnicity, year of
birth, and maternal educational level;
***Defined as combination of a history of doctor’s diagnosed asthma plus asthma symptoms or medication use in the last 12 months (beta-mimetics or inhaled
corticosteroids).
doi:10.1371/journal.pone.0087162.t002
Table 3. Lung functions of hospitalized RSV bronchiolitis patients and non-hospitalized children at the age of 6 years.
Hospitalized RSV
bronchiolitis patients Non-hospitalized Crude Adjusted*
(n=117) (n=549)





FEV1 (l) 1.24 (0.20) 93.3 (12.19) 1.43 (0.33) 100.27 (13.90) 26.97 (29.69 to
24.24)
,0.001 26.82 (210.20 to 23.44) ,0.001
FVC (l) 1.35 (0.24) 98.16 (13.81) 1.53 (0.39) 104.31 (15.55) 26.16 (29.21 to
23.11)
,0.001 26.54 (210.43 to 22.65) 0.001
FEV1/FVC (%) 92.32 (8.68) – 93.68 (5.96) 21.36 (22.75 to 0.04) 0.057 21.97 (23.61 to 20.33) 0.019
PEF (l/s) 2.86 (0.49) 98.09 (15.19) 3.17 (0.89) 101.36 (21.45) 23.28 (27.71 to 1.17) 0.148 22.93 (28.59 to 2.73) 0.310
Rint (kPa L
21 s) 0.76 (0.23) 124.72 (35.69) 0.66 (0.17) 112.73 (31.88) 11.99 (4.54 to 19.43) 0.002 15.59 (6.55 to 24.64) 0.001
FeNO (ppb)a 10.85 (9.01) – 8.12 (5.47) – 2.73 (1.15 to 4.29) 0.001 4.02 (1.88 to 6.16) 0.001
Values are expressed as % of the predicted values (mean (SD)); Presented mean differences are differences in mean %predicted values;
*Adjusted for sex, age, birth weight, birth season, smoke exposure during pregnancy and during life, breastfeeding, daycare, siblings, maternal atopy, ethnicity, year of
birth, and maternal educational level.
doi:10.1371/journal.pone.0087162.t003
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response. Production of proteases and radical oxygen species may
cause major damage to the airways resulting in abnormal
development of lung architecture and function. An alternative
hypothesis is based on our previous observations that children with
severe RSV bronchiolitis have a stronger local IL-10 response,
which may partially be genetically determined [23–25]. Increased
local IL-10 production is associated with decreased production of
type I and type 2 interferons, leaving patients susceptible to
respiratory viral infections.
Previous studies as well as ours were not designed to determine
whether RSV bronchiolitis causes airway morbidity at school age
or reflects a common predisposition, probably abnormal lung
function at birth [26]. It is clear that both hypotheses are not
mutually exclusive. We have recently shown that RSV infection is
causally related to recurrent wheeze in the first year of life in
otherwise healthy preterm infants 33–35 weeks gestational age
[27]. RSV immunoprophylaxis prevented 60% of all cause
wheeze, even after end of therapy. Similarly, intervention studies
are required to assess to what extent RSV hospitalization causes
asthma at school age, which will prove instrumental in estimating
the potential long-term benefit of new preventive and therapeutic
interventions against RSV, of which many are currently under
development [28].
In this study we assessed the unbiased risk of wheeze and
asthma in childhood after RSV bronchiolitis hospitalization.
However, some limitations need to be discussed. First, although
our study has some advantages over previous retrospective or case-
control studies, the optimal study design was not met. In our
cohort, we have actively enriched the group of children
hospitalized for RSV bronchiolitis. This led to the limitation that
we were not able to assess absolute respiratory risks of
hospitalization for RSV, but we were able to validly estimate
relative respiratory risks. Second, lung function measurement was not
successful in 42 patients (27%) in the RSV hospitalization group.
Surprisingly, children with a successful lung function were younger
compared to those without a successful lung function. As the
remaining baseline characteristics (demographics) in these children
were similar to patients with successful lung function measurements,
we think that the lung functions measured are representative of all
RSV patients. Third, we were able to obtain follow up data from 76%
of the hospitalized RSV cohort. Non-participants were more often
non-Caucasian compared to participants, which may limit the
generalizability of our results to the non-Caucasian group. Fourth,
residual confounding may have influenced our conclusions, even
though we aimed to correct for all known potential confounders.
Fifth, cohort effects may have influenced our outcomes. Although
asthma prevalence has increased over the last decades, the prevalence
of wheeze and asthma in our study is most likely not affected by the
slight variation in time periods between our cohorts. Finally, we did
not assess post bronchodilator reversibility which is thought to have
added value to make an asthma diagnosis in children [29].
In summary, this is the first prospective study comparing
previously healthy term infants hospitalized for RSV bronchiolitis
with an unselected healthy, term population. We established that
hospitalization for RSV bronchiolitis was associated with a 3.2-fold
increased risk of wheeze, a 3.1-fold increased risk of asthma and a
6.8% decrease in FEV1% predicted at age 6 compared to non-
hospitalized children. Intervention studies will have to determine
to what extent RSV bronchiolitis is causally related to long-term
airway disease.
Supporting Information
Figure S1 RSV study population at 6 years follow up.
(TIF)
Figure 1. FEV1 values presented as % predicted values for hospitalized RSV bronchiolitis patients and non-hospitalized children
measured at the age of 6 years. Hospitalized patients had a lower mean FEV1% predicted compared to non hospitalized children (93.3 (SD12.2)
versus 100.3% (SD 13.9), mean difference 27.0 (95% CI (29.7 to 24.2)).
doi:10.1371/journal.pone.0087162.g001
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Table S1 Baseline characteristics of participants, non-
participants and premature participants that were
excluded from analyses.
(DOC)
Table S2 General characteristics of the population with
and without a successful lung function measurement.
(DOCX)
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